Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company.

[2][3] With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.

[5] In April 2019, Intrexon formed a subsidiary called Precigen, with a focus on human gene therapy.

[6][7] In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing.

[8][9] With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Randal J.